Registration of the quantity of shares in Nexstim Plc

The Extraordinary General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), resolved on 21 November 2018 to reduce the quantity of Nexstim’s shares without reducing share capital by way of issuing new shares and by redemption of Company’s own shares, in such a way that each 30 shares of the Company shall corresponded to one share of the Company after the arrangements related to the reduction of the quantity of Company’s shares were completed.

Pursuant to the resolution of the Board of Directors of the Company on 24 January 2019 regarding the annulment of the Company’s own shares, which remained in the possession of the Company (as set forth in the Company announcement of the aforementioned date), the annulment of 5 shares of the Company have now been registered within the Trade Register and the final amount of shares after this is 3,253,746.

Helsinki, 31 January 2019

NEXSTIM PLC

The Board of Directors

NEXSTIM PLC

Martin Jamieson, CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com

Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
jussi.majamaa@sisupartners.com

Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
david.dible@citigatedewerogerson.com
**About Nexstim Plc**

Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit [www.nexstim.com](http://www.nexstim.com).